Novo Nordisk shares rose in premarket trade after Q2 Wegovy sales surged 67% YoY to $3.03 billion, easing concerns following last week’s record stock plunge. Despite copycat threats and Trump tariff fears, retail sentiment remains bullish. The company also named a new CEO and announced cost cuts to regain momentum, though shares remain 45% down YTD.